The mitochondriogenic but not the immunosuppressant effects of mTOR inhibitors prompt neuroprotection and delay disease evolution in a mouse model of progressive multiple sclerosis
DISCUSSION: Data corroborate the key role of mitochondriogenesis to treatment of MS progression, and for the first time disclose the translational potential of mTOR inhibitors in PMS therapy.PMID:38142841 | DOI:10.1016/j.nbd.2023.106387 (Source: Neurobiology of Disease)
Source: Neurobiology of Disease - December 24, 2023 Category: Neurology Authors: Daniela Buonvicino Sara Pratesi Giuseppe Ranieri Alessandra Pistolesi Daniele Guasti Alberto Chiarugi Source Type: research
GSE120375 Global gene expression analysis of CD14+ monocytes and CD4+ effector memory T cells before and during fingolimod treatment
Contributors : Fabienne Largey ; Ivan Jelcic ; Adam Czaplinksi ; Riccarda Capaul ; Mireia Sospedra ; Roland Martin ; Ilijas JelcicSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensTreatment of multiple sclerosis (MS) patients with sphingosine-1-phosphate receptor agonist fingolimod (FTY) increases for unknown reasons the risk for symptomatic reactivation of alpha-herpesviruses, in particular of varicella zoster virus (VZV), but not of other co-infecting herpesviruses (e.g. human cytomegalovirus (HCMV). To elucidate this specific signal in adverse events, we systematically assesse...
Source: GEO: Gene Expression Omnibus - December 21, 2023 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
Improving Data Collection in Pregnancy Safety Studies: Towards Standardisation of Data Elements in Pregnancy Reports from Public and Private Partners, A Contribution from the ConcePTION Project
CONCLUSIONS: Data access providers participating in this study presented a very high proportion of variables matching the CDE items, indicating that alignment of definitions and harmonisation of data analysis by different stakeholders to accelerate and strengthen pregnancy pharmacovigilance safety data analyses could be feasible.PMID:38114757 | DOI:10.1007/s40264-023-01384-3 (Source: Primary Care)
Source: Primary Care - December 19, 2023 Category: Primary Care Authors: Guillaume Favre Jonathan L Richardson Alan Moore Yvonne Geissb ühler Valentine Jehl Alison Oliver Svetlana Shechtman Orna Diav-Citrin Maya Berlin Tal De Haan David Baud Alice Panchaud Anil Mor Meritxell Sabid ó Sabrina de Souza Christina Chambers Yrea R Source Type: research
Improving Data Collection in Pregnancy Safety Studies: Towards Standardisation of Data Elements in Pregnancy Reports from Public and Private Partners, A Contribution from the ConcePTION Project
ConclusionsData access providers participating in this study presented a very high proportion of variables matching the CDE items, indicating that alignment of definitions and harmonisation of data analysis by different stakeholders to accelerate and strengthen pregnancy pharmacovigilance safety data analyses could be feasible. (Source: Drug Safety)
Source: Drug Safety - December 19, 2023 Category: Drugs & Pharmacology Source Type: research
Is vaccine response to SARS-CoV-2 preserved after switching to anti-CD20 therapies in patients with multiple sclerosis or related disorders?
Conclusions
Despite a primary vaccination performed before the first anti-CD20 cycle, our results suggest weaker immune responses at 6 and 12 months and decreased booster efficacy after introducing anti-CD20. Patients vaccinated prior to anti-CD20 introduction might falsely be considered as fully protected by vaccination. (Source: Journal of Neurology, Neurosurgery and Psychiatry)
Source: Journal of Neurology, Neurosurgery and Psychiatry - December 14, 2023 Category: Neurosurgery Authors: Jeantin, L., Abdi, B., Soulie, C., Sterlin, D., Maillart, E., Beigneux, Y., Hippolyte, A., Belin, L., Marcelin, A.-G., Pourcher, V., Louapre, C. Tags: COVID-19 Multiple sclerosis Source Type: research
Humoral Response to SARS-COV-2 Vaccination in Patients with Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder: A Real-World Study
ConclusionsTreatment with aCD20 or SP1-M therapies appears to be associated with a lower humoral response to vaccines against SARS-CoV-2. Vaccination prior to initiation of these DMTs should be recommended whenever possible. (Source: Neurology and Therapy)
Source: Neurology and Therapy - December 14, 2023 Category: Neurology Source Type: research
Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom
CONCLUSIONS: This MSBase Registry analysis suggests that natalizumab improves clinical outcomes when compared with fingolimod, which translates to higher QALYs and lower costs in UK patients with RES-RRMS.PMID:38085684 | DOI:10.1080/13696998.2023.2293379 (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - December 12, 2023 Category: Health Management Authors: T Spelman W L Herring C Acosta R Hyde V G Jokubaitis E Pucci A Lugaresi G Laureys E K Havrdova D Horakova G Izquierdo S Eichau S Ozakbas R Alroughani T Kalincik P Duquette M Girard T Petersen F Patti T Csepany F Granella F Grand'Maison D Ferraro R Karabud Source Type: research
The Role of Serum Monocytes and Tissue Macrophages in Driving Left Ventricular Systolic Dysfunction and Cardiac Inflammation Following Subarachnoid Hemorrhage
ConclusionsIncreased serum leukocytes are associated with abnormal left ventricular systolic function following aSAH. The strongest independent predictor of both reduced and hyperdynamic systolic function was increased monocytes. Increased cardiac macrophages after experimental SAH can also be targeted by using immunomodulatory drugs. (Source: Neurocritical Care)
Source: Neurocritical Care - December 7, 2023 Category: Neurology Source Type: research
Fingolimod (FTY720), an FDA ‐approved sphingosine 1‐phosphate (S1P) receptor agonist, restores endothelial hyperpermeability in cellular and animal models of dengue virus serotype 2 infection
AbstractExtensive vascular leakage and shock is a major cause of dengue-associated mortality. At present, there are no specific treatments available. Sphingolipid pathway is a key player in the endothelial barrier integrity; and is mediated through the five sphingosine-1-phosphate receptors (S1PR1-S1PR5). Signaling through S1PR2 promotes barrier disruption; and in Dengue virus (DENV)-infection, there is overexpression of this receptor. Fingolimod (FTY720) is a specific agonist that targets the remaining barrier-protective S1P receptors, without targeting S1PR2. In the present study, we explored whether FTY720 treatment can...
Source: IUBMB Life - December 1, 2023 Category: Research Authors: Ayan Modak,
Srishti Rajkumar Mishra,
Mansi Awasthi,
Arya Aravind,
Sneha Singh,
Easwaran Sreekumar Tags: SPECIAL ISSUE Source Type: research
EE195 Quantifying the Avoided Costs of a Switch to Ofatumumab From Low/Moderate Efficacy Disease Modifying Therapies in Patients With Relapsing-Remitting Multiple Sclerosis in Colombia
The objective of this researh was to quantify the avoided direct medical costs for the Colombian healthcare perspective by switching patients currently treated with LME-DMT to Ofatumumab. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: M. Ceballos Gonz ález, P. Castro Source Type: research
